NETRIS Pharma Press Releases - EIN Presswire - Press Release Distribution Service

Published on October 19, 2025 - 07:00 GMT

NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at ESMO 2025

Primary efficacy endpoint met in secondary refractory patients LYON, FRANCE, October 19, 2025 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biotechnology company pioneering novel therapies targeting Netrin-1 to overcome resistance to …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 18, 2025 - 06:00 GMT

NETRIS Pharma appoints Dr. Sébastien Hazard as Chief Medical Officer to Lead Next Phase of Clinical Development

NETRIS Pharma is advancing its pipeline into later-stage clinical trials LYON, FRANCE, September 18, 2025 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biotechnology company developing first-in-class therapeutics targeting Netrin-1 and its role …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on April 25, 2025 - 06:00 GMT

NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1

Confirmation of NP137 Potential to Overcome Resistance to Immune Checkpoint - Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025 LYON, FRANCE, April 25, 2025 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage private …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on December 3, 2024 - 07:00 GMT

NETRIS Pharma Welcomes Eric Falcand as Independent Director to Its Board of Directors

LYON, FRANCE AND GENEVA , SWITZERLAND, December 3, 2024 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a leading clinical-stage biopharmaceutical company dedicated to advancing the next generation of molecules targeting cancer resistance, today announced the …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on November 21, 2024 - 07:00 GMT

NETRIS Pharma Announces FDA Orphan Drug Designation (ODD) for NP137 in Pancreatic Cancer Treatment

LYON, FRANCE, AND GENEVA, SWITZERLAND, November 21, 2024 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biopharmaceutical company pioneering therapies to overcome resistance in oncology, today announced that the U.S. Food and Drug Administration ( …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 4, 2024 - 06:00 GMT

NETRIS Pharma appoints Segolène BISOT-LOCARD as Chief Medical Officer

NETRIS Pharma poised to advance into the next phase of clinical development LYON, FRANCE, September 4, 2024 /⁨EINPresswire.com⁩/ -- LYON, France and GENEVA, Switzerland– NETRIS PHARMA today announced the appointment Ségolène BISOT-LOCARD, MD, as Chief …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 23, 2024 - 06:00 GMT

NETRIS Pharma awarded €3.9m to Lead the Development of a Novel Therapy in Endometriosis

EndoNETherapy aims at delivering the First Non-Hormonal Disease Modifying Therapy for patients suffering from Endometriosis LYON, RHONE, FRANCE, May 23, 2024 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage private biopharmaceutical company …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on December 19, 2023 - 07:00 GMT

NETRIS Pharma extends Series A to €24.4 million and reinforces its leadership team and Board of Directors

Proceeds of €7.5m to enable the completion of 5 ongoing phase 2 clinical studies LYON, FRANCE, December 19, 2023 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on August 30, 2023 - 06:00 GMT

NETRIS Pharma: data published in 2 Nature papers confirm netrin-1 blockade as significant clinical strategy in oncology

Netrin-1 blockade with NP137 confirmed as a clinical strategy in oncology to alleviate resistance to standard treatments LYON, FRANCE, August 30, 2023 /⁨EINPresswire.com⁩/ -- > Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...